U
Petlife Pharmaceuticals, Inc.
PTLF
$0.0001
$0.000.00%
D
Sell
11/26/2018Downgrade
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 11/26/2018 due to a decline in the volatility index.
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 11/26/2018 due to a decline in the volatility index.
D
Sell
8/27/2018Upgraded
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 8/27/2018 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.0063 to -$0.0057, and EBIT increased 5.48% from -$193.3 to -$182.7.
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 8/27/2018 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.0063 to -$0.0057, and EBIT increased 5.48% from -$193.3 to -$182.7.
D
Sell
12/15/2017Downgrade
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 12/15/2017 due to a noticeable decline in the growth index and volatility index. EBIT declined 155.75% from -$572 to -$1.46M, and earnings per share declined from -$0.013 to -$0.0138.
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 12/15/2017 due to a noticeable decline in the growth index and volatility index. EBIT declined 155.75% from -$572 to -$1.46M, and earnings per share declined from -$0.013 to -$0.0138.
D
Sell
8/8/2017Upgraded
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 8/8/2017 due to an increase in the total return index and volatility index.
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 8/8/2017 due to an increase in the total return index and volatility index.
D
Sell
7/24/2017Downgrade
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 7/24/2017 due to a substantial decline in the total return index and volatility index.
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 7/24/2017 due to a substantial decline in the total return index and volatility index.
D
Sell
2/10/2017Upgraded
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 2/10/2017 due to a significant increase in the efficiency index, total return index and growth index.
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 2/10/2017 due to a significant increase in the efficiency index, total return index and growth index.
D
Sell
12/22/2016Downgrade
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from C- on 12/22/2016 due to a significant decline in the efficiency index, growth index and total return index. Net income declined 2,579.35% from -$124 to -$3.32M, EBIT declined 2,579.35% from -$124 to -$3.32M, and earnings per share declined from -$0.0163 to -$0.3319.
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from C- on 12/22/2016 due to a significant decline in the efficiency index, growth index and total return index. Net income declined 2,579.35% from -$124 to -$3.32M, EBIT declined 2,579.35% from -$124 to -$3.32M, and earnings per share declined from -$0.0163 to -$0.3319.
C
Hold
8/8/2016Upgraded
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to C- from D+ on 8/8/2016 due to a major increase in the total return index.
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to C- from D+ on 8/8/2016 due to a major increase in the total return index.
D
Sell
7/22/2016Upgraded
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 7/22/2016 due to a noticeable increase in the growth index, total return index and efficiency index. EBIT increased 4.98% from -$130.5 to -$124, net income increased 4.98% from -$130.5 to -$124, and earnings per share increased from -$0.0034 to -$0.0033.
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 7/22/2016 due to a noticeable increase in the growth index, total return index and efficiency index. EBIT increased 4.98% from -$130.5 to -$124, net income increased 4.98% from -$130.5 to -$124, and earnings per share increased from -$0.0034 to -$0.0033.
D
Sell
7/12/2016Downgrade
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 7/12/2016 due to a decline in the volatility index and valuation index.
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 7/12/2016 due to a decline in the volatility index and valuation index.
D
Sell
6/21/2016Upgraded
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 6/21/2016 due to an increase in the volatility index.
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 6/21/2016 due to an increase in the volatility index.
D
Sell
4/20/2016Downgrade
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 4/20/2016 due to a decline in the growth index and valuation index. Earnings per share declined from -$0.002 to -$0.0034, and EBIT declined 18.53% from -$110.1 to -$130.5.
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 4/20/2016 due to a decline in the growth index and valuation index. Earnings per share declined from -$0.002 to -$0.0034, and EBIT declined 18.53% from -$110.1 to -$130.5.
D
Sell
4/18/2016Upgraded
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 4/18/2016 due to an increase in the total return index and volatility index.
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to D+ from D on 4/18/2016 due to an increase in the total return index and volatility index.
D
Sell
3/11/2016Downgrade
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from C- on 3/11/2016 due to a major decline in the volatility index and total return index.
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from C- on 3/11/2016 due to a major decline in the volatility index and total return index.
C
Hold
1/15/2016Upgraded
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to C- from D on 1/15/2016 due to an increase in the growth index and total return index. EBIT increased 442.36% from -$20.3 to -$110.1, and earnings per share increased from -$0.0004 to -$0.002.
Petlife Pharmaceuticals, Inc. (PTLF) was upgraded to C- from D on 1/15/2016 due to an increase in the growth index and total return index. EBIT increased 442.36% from -$20.3 to -$110.1, and earnings per share increased from -$0.0004 to -$0.002.
D
Sell
1/4/2016Downgrade
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 1/4/2016 due to a major decline in the growth index, solvency index and valuation index. EBIT declined 97.85% from -$445.9 to -$9.6, earnings per share declined from -$0.0077 to -$0.0002, and the quick ratio declined from 0.01 to 0.01.
Petlife Pharmaceuticals, Inc. (PTLF) was downgraded to D from D+ on 1/4/2016 due to a major decline in the growth index, solvency index and valuation index. EBIT declined 97.85% from -$445.9 to -$9.6, earnings per share declined from -$0.0077 to -$0.0002, and the quick ratio declined from 0.01 to 0.01.
D
Sell
7/22/2014Upgraded
Clear TV Ventures, Inc. (EVGI) was upgraded to D+ from D on 7/22/2014 due to an increase in the growth index, solvency index and total return index. Debt to equity declined from 0.57 to 0.23.
Clear TV Ventures, Inc. (EVGI) was upgraded to D+ from D on 7/22/2014 due to an increase in the growth index, solvency index and total return index. Debt to equity declined from 0.57 to 0.23.
D
Sell
2/28/2014Downgrade
Eco Ventures Group, Inc. (EVGI) was downgraded to D from D+ on 2/28/2014 due to a decline in stability.
Eco Ventures Group, Inc. (EVGI) was downgraded to D from D+ on 2/28/2014 due to a decline in stability.
OTC PK
02/26/2025 2:31PM Eastern
Quotes delayed
